Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Masoprocol - TriAct Therapeutics

Next Previous
X
Search
Drug Profile

Masoprocol - TriAct Therapeutics

Alternative Names: INS-18; INSM-18; Masoprocal; TT-100

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Insmed
  • Developer Insmed; University of California at San Francisco
  • Class Anti-inflammatories; Catechols; Lignans; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Insulin-like growth factor I inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 27 Jul 2016 No development reported - Phase-II for Prostate cancer in USA (PO)
  • 06 Mar 2014 Phase II development is ongoing in USA
  • 01 Jun 2011 University of California at San Francisco terminates a phase II trial in Prostate cancer in USA due to lack of efficacy (NCT00678015)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top